Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Lai

Showing results (141-150 of 209) with videos related to

Pageof 21
Sort By:
Neuro-Oncology Advances|May 12, 2026
A single-institution retrospective study of multicentric gliomas stratified by <i>IDH</i> mutational statusChuyin Yang, Ryan Mostafavi, Collin Le, et al.
Plos One|October 28, 2015
Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma PatientsWilliam H Yong, Maryam Shabihkhani, Donatello Telesca, et al.
Neuro-Oncology|August 31, 2016
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapyHuyTram N Nguyen, Amy Lie, Tie Li, et al.
Iscience|August 30, 2020
Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet TherapyJantzen Sperry, Michael C Condro, Lea Guo, et al.
ACS Medicinal Chemistry Letters|May 31, 2021
Discovery of a Potent and Selective Covalent p300/CBP InhibitorAnthony Mastracchio, Chunqiu Lai, Enrico Digiammarino, et al.
Neuro-Oncology|May 9, 2019
Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRIJingwen Yao, Ararat Chakhoyan, David A Nathanson, et al.
Neuro-Oncology Advances|March 7, 2025
A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastomaBenjamin M Ellingson, Qunicy Okobi, Robert Chong, et al.
Neuro-Oncology|September 1, 2025
Perfusion, diffusion, and anatomical MRI characteristics of pathologically-confirmed malignant transformation in IDH-mutant gliomasNicholas S Cho, Viên Lam Le, Ashley Teraishi, et al.
Cancer Research Communications|March 6, 2024
D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A HypermethylationSean T Pianka, Tie Li, Terry J Prins, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy AssessmentXiao-Tang Kong, Nhung T Nguyen, Yoon J Choi, et al.
Pageof 21

Showing results (141-150 of 209) with videos related to

Sort By:
Pageof 21
Neuro-Oncology Advances|May 12, 2026
A single-institution retrospective study of multicentric gliomas stratified by <i>IDH</i> mutational statusChuyin Yang, Ryan Mostafavi, Collin Le, et al.
Plos One|October 28, 2015
Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma PatientsWilliam H Yong, Maryam Shabihkhani, Donatello Telesca, et al.
Neuro-Oncology|August 31, 2016
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapyHuyTram N Nguyen, Amy Lie, Tie Li, et al.
Iscience|August 30, 2020
Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet TherapyJantzen Sperry, Michael C Condro, Lea Guo, et al.
ACS Medicinal Chemistry Letters|May 31, 2021
Discovery of a Potent and Selective Covalent p300/CBP InhibitorAnthony Mastracchio, Chunqiu Lai, Enrico Digiammarino, et al.
Neuro-Oncology|May 9, 2019
Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRIJingwen Yao, Ararat Chakhoyan, David A Nathanson, et al.
Neuro-Oncology Advances|March 7, 2025
A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastomaBenjamin M Ellingson, Qunicy Okobi, Robert Chong, et al.
Neuro-Oncology|September 1, 2025
Perfusion, diffusion, and anatomical MRI characteristics of pathologically-confirmed malignant transformation in IDH-mutant gliomasNicholas S Cho, Viên Lam Le, Ashley Teraishi, et al.
Cancer Research Communications|March 6, 2024
D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A HypermethylationSean T Pianka, Tie Li, Terry J Prins, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy AssessmentXiao-Tang Kong, Nhung T Nguyen, Yoon J Choi, et al.
Pageof 21